Bristol-Myers Enterprise Value Trend from 2010 to 2021

BMY -  USA Stock  

USD 66.47  0.30  0.45%

Bristol-Myers Squibb Enterprise Value yearly trend continues to be fairly stable with very little volatility. Enterprise Value will likely drop to about 141.6 B in 2021. During the period from 2010 to 2021, Bristol-Myers Squibb Enterprise Value regression line of anual values had slope of 7,865,759,874 and arithmetic mean of  97,913,343,435. Bristol-Myers Squibb Direct Expenses is fairly stable at the moment as compared to the past year. Bristol-Myers Squibb reported Direct Expenses of 11.77 Billion in 2020. Net Income to Non Controlling Interests is likely to rise to about 20.5 M in 2021, whereas Consolidated Income is likely to drop (9.2 B) in 2021.

Search Historical Trends 

 
Refresh
Check Bristol-Myers Squibb financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol-Myers main balance sheet or income statement drivers, such as Direct Expenses of 12.7 B, Cost of Revenue of 9.6 B or Gross Profit of 25.3 B, as well as many exotic indicators such as Interest Coverage of 10.64, Long Term Debt to Equity of 1.38 or Calculated Tax Rate of 24.75. Bristol-Myers financial statements analysis is a perfect complement when working with Bristol-Myers Squibb Valuation or Volatility modules. It can also supplement various Bristol-Myers Squibb Technical models. Continue to the analysis of Bristol-Myers Squibb Correlation against competitors.

Bristol-Myers Squibb Quarterly Enterprise Value

177.57 BillionShare

Bristol-Myers Enterprise Value Breakdown

Showing smoothed Enterprise Value of Bristol-Myers Squibb with missing and latest data points interpolated. Enterprise Value (or EV) is usually referred to as Bristol-Myers Squibb theoretical takeover price. In the event of an acquisition, an acquirer would have to take on Bristol-Myers Squibb debt, but would also pocket its cash. Enterprise Value is more accurate representation of Bristol-Myers Squibb value than its market capitalization because it takes into account all of Bristol-Myers Squibb existing debt. Enterprise value is a measure of the value of a business as a whole; calculated as Market Capitalization plus Total Debt USD minus Cash and Equivalents USD.Bristol-Myers Squibb's Enterprise Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol-Myers Squibb's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 176.99 B10 Years Trend
Increasing
Slightly volatile
 Enterprise Value 
Share
      Timeline 

Bristol-Myers Enterprise Value Regression Statistics

Arithmetic Mean 97,913,343,435
Geometric Mean 92,221,743,655
Coefficient Of Variation 34.85
Mean Deviation 24,148,266,770
Median 100,734,576,264
Standard Deviation 34,121,260,390
Range 121,219,958,303
R-Value 0.83
R-Squared 0.69
Significance 0.00080774
Slope 7,865,759,874

Bristol-Myers Enterprise Value History

201160.9 B
201259.7 B
201393 B
2014100.7 B
2015118.1 B
2016101.1 B
2017104.1 B
201886.7 B
201999.1 B
2020165.7 B
2021141.6 B

Other Fundumenentals of Bristol-Myers Squibb

About Bristol-Myers Squibb Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol-Myers Squibb income statement, its balance sheet, and the statement of cash flows. Bristol-Myers Squibb investors use historical funamental indicators, such as Bristol-Myers Squibb's Enterprise Value, to determine how well the company is positioned to perform in the future. Although Bristol-Myers Squibb investors may use each financial statement separately, they are all related. The changes in Bristol-Myers Squibb's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol-Myers Squibb's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol-Myers Squibb Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol-Myers Squibb. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Enterprise Value over EBIT(24.00) (24.63) 
Enterprise Value over EBITDA 47.49  38.80 
Enterprise Value165.7 B141.6 B
Tangible Asset Value44.7 B39.9 B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 30250 people.

Bristol-Myers Squibb Investors Sentiment

The influence of Bristol-Myers Squibb's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bristol-Myers. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - BMY

Bristol-Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol-Myers Squibb. What is your opinion about investing in Bristol-Myers Squibb? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Trading with Bristol-Myers Squibb

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.

Bristol-Myers Squibb Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol-Myers Squibb and Grifols SA. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Bristol-Myers Squibb Correlation against competitors. Note that the Bristol-Myers Squibb information on this page should be used as a complementary analysis to other Bristol-Myers Squibb's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Bristol-Myers Squibb Stock analysis

When running Bristol-Myers Squibb price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol-Myers that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol-Myers Squibb's value that differs from its market value or its book value, called intrinsic value, which is Bristol-Myers Squibb's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol-Myers Squibb's market value can be influenced by many factors that don't directly affect Bristol-Myers Squibb underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol-Myers Squibb's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol-Myers Squibb value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.